middl
east
respiratori
syndrom
coronaviru
merscov
novel
lethal
human
viru
famili
coronavirida
first
identifi
saudi
arabia
june
infect
pathogen
caus
acut
respiratori
diseas
design
mer
symptom
similar
global
merscov
infect
confirm
countri
caus
death
http
wwwwhointemergenciesmerscoven
interspeci
transmiss
dromedari
camel
human
consid
one
major
rout
transmiss
middl
east
howev
mani
infect
patient
without
camel
exposur
recent
mer
outbreak
korea
demonstr
largescal
humantohuman
transmiss
occur
close
due
potenti
mutat
toward
effici
humantohuman
transmiss
caus
pandem
merscov
list
categori
c
prioriti
pathogen
us
nation
institut
allergi
infecti
diseas
monoclon
antibodi
mab
potent
neutral
activ
becom
promis
candid
prophylact
therapeut
intervent
viral
coronavirus
compon
primarili
target
mab
homotrimer
spike
glycoprotein
virion
typic
class
fusion
glycoprotein
trimer
highli
pathogen
coronavirus
merscov
sarscov
mediat
receptor
recognit
membran
fusion
viral
undergo
proteas
cleavag
subunit
posit
chang
receptorbind
domain
rbd
subunit
receptor
bind
dissoci
complex
final
format
sixhelix
bundl
subunit
seri
rbdtarget
antibodi
merscov
block
bind
trimer
cellular
receptor
report
antibodi
exhibit
high
potenc
inhibit
infect
pseudotyp
live
merscov
cell
anim
model
neutral
epitop
mechan
antibodi
includ
elucid
atom
level
structur
function
sequenc
comparison
differ
merscov
strain
shown
natur
occur
mutat
glycoprotein
locat
rbd
subunit
subunit
consid
rapid
evolut
high
genom
variat
rna
virus
mutat
rbd
may
enabl
new
strain
escap
neutral
current
known
rbdtarget
antibodi
therefor
new
mab
target
function
region
merscov
glycoprotein
andor
neutral
differ
mechan
import
develop
effect
prophylact
therapeut
intervent
merscov
infect
although
sever
mab
target
nonrbd
region
recent
report
neutral
epitop
mechan
remain
studi
isol
character
mous
mab
combin
structur
biochem
function
studi
antibodi
recogn
ntd
merscov
glycoprotein
neutral
infect
pseudotyp
live
viru
potenc
compar
activ
rbdtarget
antibodi
also
found
epitop
mechan
differ
rbdtarget
antibodi
enabl
better
neutral
breadth
work
synergist
antibodi
differ
merscov
strain
result
indic
promis
candid
futur
combin
use
differ
antibodi
battl
merscov
gener
merscov
neutral
mab
epitop
outsid
rbd
mice
immun
recombin
merscov
protein
residu
subsequ
spleenocyt
harvest
fuse
myeloma
cell
hybridoma
cell
line
screen
posit
clone
elisa
posit
clone
test
reactiv
differ
fragment
includ
subunit
ntd
residu
rbd
residu
subunit
residu
one
ntdspecif
mab
name
final
isol
approxim
elisa
fig
exhibit
crossreact
rbd
concentr
fig
assess
potenti
form
crude
extract
mous
ascit
inhibit
merscov
entri
suscept
cell
vero
cell
either
pseudotyp
infecti
virus
expect
abl
neutral
infect
pseudotyp
live
merscov
fig
neutral
activ
dosedepend
approxim
pseudotyp
viru
practic
approxim
live
viru
emc
strain
fig
imag
illustr
reduc
pfu
format
correspond
rate
neutral
live
merscov
shown
fig
antibodi
isotyp
show
belong
subtyp
sequenc
determin
heavi
chain
germlin
v
j
segment
light
chain
respect
supplementari
tabl
also
gener
chimer
version
combin
v
segment
human
backbon
effici
express
purifi
freestyl
cell
supplementari
fig
biolay
interferometri
bli
experi
show
affin
constant
bind
ntd
approxim
nm
tabl
supplementari
fig
purifi
cell
entri
pseudotyp
merscov
approxim
supplementari
fig
also
investig
protect
efficaci
infect
pseudotyp
merscov
use
mice
model
human
insert
locu
could
also
product
infect
hightit
merscov
pseudoviru
effect
compar
authent
bioluminesc
fluc
report
show
pseudoviru
infect
mice
clearli
prevent
rbdspecif
mab
antibodi
administ
intraperiton
inject
dose
per
mous
supplementari
fig
recombin
chimer
retain
activ
mous
protect
mice
challeng
pseudotyp
merscov
util
subsequ
bind
neutral
experi
structur
character
bind
spike
protein
determin
crystal
structur
antibodi
scfv
complex
ntd
resolut
final
rwork
rfree
statist
diffract
data
collect
process
structur
refin
list
tabl
three
complex
bound
ntd
per
asymmetr
unit
refin
model
contain
residu
merscov
ntd
vh
vl
nlink
glycan
attach
ntd
also
includ
model
previous
shown
merscov
ntd
fold
galectinlik
structur
separ
top
core
bottom
subdomain
fig
upon
bind
contact
top
subdomain
ntd
glycan
heavi
light
chain
fig
supplementari
fig
three
cdr
heavi
chain
light
chain
particip
bind
fig
buri
surfac
ntd
encompass
approxim
heavi
chain
light
chain
bind
interfac
ntd
consist
residu
glycan
ntd
well
residu
cdr
except
fig
c
interact
residu
ntd
togeth
form
conform
epitop
recogn
fig
residu
recogn
fig
specif
residu
interact
ntd
form
hydrogen
bond
ntd
fig
supplementari
tabl
contribut
recognit
via
interact
ntd
two
hydrogen
bond
form
ntd
fig
supplementari
tabl
compar
engag
ntd
extens
interact
ntd
fig
form
two
hydrogenbond
interact
ntd
supplementari
tabl
light
chain
residu
interact
ntd
salt
bridg
form
ntd
fig
supplementari
tabl
promin
featur
interfac
extens
recognit
glycan
three
heavi
chain
cdr
fig
supplementari
tabl
specif
hydrogenbond
interact
occur
glycan
respect
fig
supplementari
tabl
confirm
epitop
critic
residu
perform
mutagenesi
studi
introduc
singl
mutat
ntd
recogn
residu
includ
first
examin
effect
ntd
mutat
bind
bound
wildtyp
ntd
affin
approxim
nm
tabl
supplementari
fig
contrast
mutat
dramat
reduc
bind
level
undetect
bli
experi
tabl
supplementari
fig
mutat
reduc
bind
affin
respect
tabl
supplementari
fig
nine
mutat
variant
unequ
effect
bind
reduc
affin
rang
tabl
supplementari
fig
effect
mutat
neutral
activ
consist
chang
bind
affin
pseudotyp
merscov
bear
mutat
spike
glycoprotein
escap
neutral
tabl
supplementari
fig
valu
pseudotyp
merscov
bear
mutat
increas
approxim
tabl
supplementari
fig
bind
neutral
assay
collect
reveal
glycan
critic
recognit
neutral
merscov
sequenc
multipl
clinic
isol
reveal
merscov
glycoprotein
evolv
averag
rate
substitut
per
site
per
align
deposit
sequenc
ncbi
identifi
natur
chang
residu
prototyp
emc
sequenc
includ
locat
ntd
residu
rbd
residu
subunit
subunit
residu
sever
residu
chang
rbd
occur
inde
enabl
merscov
escap
neutral
antibodi
target
consid
mutat
outsid
ntd
specul
would
better
toler
natur
occur
mutat
gener
pseudotyp
merscov
bear
emc
strain
glycoprotein
mutant
harbor
list
residu
chang
neutral
assay
show
show
effect
neutral
activ
almost
pseudotyp
merscov
variant
two
mutat
ntd
increas
valu
significantli
reduc
neutral
activ
fig
b
confirm
result
structur
biochem
studi
bind
interfac
natur
occur
mutat
rbd
subunit
affect
neutral
capabl
fig
b
indic
would
wide
neutral
breadth
differ
variant
merscov
current
avail
merscov
antibodi
epitop
solv
structur
rbd
group
three
categori
epitop
epitop
epitop
newli
report
supplementari
fig
studi
rbdspecif
mab
also
found
synerg
ntdtarget
mab
thu
elucid
epitop
target
ad
categori
outsid
rbd
supplementari
fig
prompt
us
studi
combin
effect
togeth
three
repres
antibodi
neutral
pseudotyp
merscov
titrat
neutral
potenc
equimolar
mixtur
two
antibodi
compar
dose
respons
observ
neutral
assay
perform
individu
antibodi
alon
shown
fig
combin
index
ci
valu
combin
fa
valu
effect
dose
respect
respect
ci
valu
indic
addit
effect
indic
synerg
indic
antagon
combin
work
clearli
synergist
manner
meanwhil
combin
index
ci
valu
combin
fa
valu
effect
dose
respect
thu
combin
also
demonstr
synerg
particular
rel
lower
concentr
howev
percent
neutral
obtain
use
combin
show
obviou
differ
half
maxim
inhibitori
concentr
compar
alon
combin
index
ci
valu
combin
fa
valu
effect
dose
respect
indic
combin
exhibit
neither
synergi
antagon
major
report
merscov
neutral
mechan
reli
inhibit
bind
trimer
cellular
receptor
epitop
report
antibodi
resid
rbd
respons
receptor
bind
fact
epitop
outsid
rbd
indic
may
differ
neutral
mechan
first
examin
still
abl
inhibit
receptor
bind
trimer
fac
analysi
cellsurfac
stain
show
scfv
fab
fragment
inhibit
stain
cell
trimer
slightli
reduc
stain
fig
supplementari
tabl
supplementari
fig
contrast
rbdtarget
mab
much
potent
inhibit
bind
trimer
cell
moreov
fab
scfv
fragment
retain
nearli
potenc
inhibit
fig
supplementari
tabl
surfac
plasmon
reson
spr
analysi
confirm
conclus
show
fab
scfv
fragment
could
interfer
bind
trimer
chipcoupl
dosedepend
manner
supplementari
fig
igg
fab
scfv
inhibit
bind
supplementari
fig
investig
igg
fab
scfv
inhibit
receptor
bind
differ
construct
model
bind
trimer
merscov
trimer
structur
determin
cryoem
rbd
stand
lie
posit
stand
rbd
could
bind
receptor
superimpos
crystal
structur
onto
trimer
observ
steric
clash
three
ntdbound
scfv
fragment
one
two
rbdbound
receptor
fig
supplementari
fig
trimer
three
rbdbound
receptor
consid
cryoem
studi
merscov
trimer
reveal
conform
one
two
stand
rbd
scfv
replac
fab
also
steric
clash
fab
receptor
fig
complic
model
bind
trimer
consid
igg
form
two
bind
site
intrins
flexibl
found
bind
igg
ntd
certain
orient
could
inhibit
bind
due
steric
clash
still
steric
clash
bound
orient
fig
e
result
provid
structur
explan
inabl
scfv
fab
inhibit
bind
trimer
receptor
may
also
explain
igg
form
potent
igg
fab
scfv
directli
bind
rbd
parallel
biochem
studi
also
examin
neutral
activ
igg
fab
scfv
fab
scfv
interfer
bind
trimer
receptor
howev
still
abl
inhibit
cell
entri
pseudotyp
merscov
valu
respect
fig
although
fab
scfv
less
activ
igg
infect
inhibit
still
compar
fab
scfv
fragment
sever
report
rbdtarget
antibodi
fab
scfv
supplementari
fig
result
collect
indic
neutral
involv
mechan
besid
interf
initi
receptor
bind
test
compar
neutral
activ
preattach
postattach
set
cell
attach
still
abl
inhibit
infect
pseudotyp
merscov
fig
comparison
potent
inhibit
receptor
bind
exhibit
weak
neutral
receptor
bind
supplementari
fig
result
especi
retain
activ
viral
attach
indic
would
also
interfer
prefus
postfus
conform
transit
glycoprotein
requir
membran
fusion
transit
influenc
proteas
cleavag
receptor
bind
antibodi
biochem
studi
monitor
appear
proteinasekresist
band
sodium
dodecyl
sulphat
sdspage
gel
compris
postfus
sixhelix
show
merscov
glycoprotein
prefus
state
sensit
digest
proteinas
k
fig
previou
studi
demonstr
cleavag
site
trypsin
bind
cellular
receptor
greatli
enhanc
prefus
postfus
transit
spike
consist
amount
kda
proteinasekresist
band
glycoprotein
repres
postfus
sixhelix
bundl
maximum
level
presenc
trypsin
fig
addit
fab
obvious
reduc
intens
band
fig
meanwhil
analyz
fulllength
merscov
trimer
embed
membran
pseudotyp
viru
trigger
use
induc
conform
transit
incub
huh
cell
endogen
express
receptor
incub
pseudotyp
viru
huh
cell
h
proteinasek
resist
band
sdspage
gel
appear
addit
fab
scfv
clearli
decreas
intens
band
supplementari
fig
thu
biochem
result
strongli
suggest
could
also
exert
neutral
activ
postattach
stage
receptorbind
inhibit
conform
transit
glycoprotein
requir
membran
fusion
fig
sinc
emerg
merscov
effect
measur
counteract
infect
becom
major
research
focu
although
antimerscov
therapi
avail
yet
neutral
mab
inhibitori
peptid
glycoprotein
demonstr
efficaci
merscov
infect
cell
anim
report
neutral
antibodi
target
rbd
block
interact
cellular
receptor
critic
step
viral
cell
attach
studi
first
isol
neutral
mous
antibodi
target
ntd
glycoprotein
neutral
assay
show
highli
potent
activ
compar
potent
rbdtarget
antibodi
structur
determin
scfv
bound
ntd
mutagenesi
studi
reveal
epitop
key
residu
ntd
bind
neutral
atom
level
comparison
scfv
fab
igg
form
competit
neutral
assay
indic
activ
sole
depend
inhibit
bind
experi
indic
neutral
activ
cell
attach
inhibit
prefus
postfus
conform
transit
glycoprotein
trimer
mediat
fusion
viral
cell
membran
also
show
wide
neutral
breadth
merscov
variant
bear
natur
occur
mutat
exhibit
synergist
effect
sever
rbdtarget
antibodi
result
collect
reveal
antibodi
epitop
neutral
mechan
glycoprotein
would
contribut
global
effort
control
merscov
infect
transmiss
provid
altern
merscov
immunotherapi
similar
ntd
protein
betacoronavirus
mhv
bcov
merscov
also
fold
galectinlik
structur
although
galectin
domain
typic
carbohydraterecognit
domain
betacoronaviru
ntd
includ
structur
variat
enabl
divers
function
viral
infect
exampl
includ
ntd
bcov
retain
glycanbind
activ
recogn
acid
ntd
mhv
evolv
specif
interact
cellular
receptor
interact
import
viral
cell
howev
still
report
glycan
proteinbind
activ
merscov
ntd
fact
crystallograph
structur
determin
show
glycanbind
site
merscov
ntd
occupi
short
helix
residu
glycan
indic
abl
bind
glycan
way
ntd
notabl
glycan
involv
recognit
wherebi
undergo
specif
hydrogenbond
interact
respect
ntd
mutat
also
dramat
reduc
bind
neutral
dramat
affect
cell
infect
pseudotyp
merscov
supplementari
fig
therefor
glycan
serv
import
anchor
point
bind
merscov
ntd
largest
class
viral
fusion
protein
coronaviru
glycoprotein
expect
undergo
prefus
postfus
conform
transit
mediat
interact
viral
cellular
membran
protein
although
structur
studi
began
shed
light
recent
glycoprotein
betacoronavirus
mhv
whose
structur
determin
cryoem
method
adopt
similar
prefus
homotrimer
interestingli
prefus
architectur
trimer
highli
pathogen
merscov
sarscov
two
major
conform
state
observ
major
differ
chang
rbd
subunit
posit
propos
prerequisit
bind
trimer
respect
cellular
receptor
propos
recent
confirm
cryoem
studi
sarscov
trimer
complex
also
show
could
induc
dissoci
subunit
result
fall
apart
prefus
trimer
transit
prefus
state
major
neutral
mechan
antibodi
merscov
directli
indirectli
compet
cellular
receptor
bind
rbd
theori
antibodi
interfer
coronaviru
membran
fusion
process
receptor
bind
would
also
neutral
activ
mab
target
ntd
studi
one
exampl
show
neutral
sole
depend
competit
inhibit
trimer
conform
transit
cell
attach
also
play
signific
role
neutral
suggest
bind
may
stabil
prefus
architectur
trimer
even
bind
receptor
stabil
viral
fusion
protein
one
conform
state
neutral
also
observ
studi
virus
hiv
recent
studi
reveal
hiv
env
trimer
intrins
dynam
three
major
distinct
prefus
among
close
groundstat
conform
domin
could
remodel
anoth
two
conform
receptor
bind
essenti
subsequ
prefus
postfus
bind
neutral
antibodi
whether
inhibit
bind
receptor
result
stabil
groundstat
conform
env
final
disfavor
prefus
postfus
state
transit
requir
viral
best
knowledg
studi
offer
first
structur
definit
neutral
epitop
antibodi
target
ntd
merscov
summar
supplementari
tabl
total
six
antintd
mab
neutral
infect
pseudotyp
merscov
emc
strain
high
potenc
except
mab
mab
show
neutral
activ
live
merscov
plaqu
reduct
neutral
test
notabl
mous
mab
greatli
reliev
symptom
mice
infect
follow
merscov
infect
inhibit
infect
pseudotyp
merscov
mice
howev
specif
neutral
epitop
mechan
larg
unknown
addit
combin
differ
antibodi
suppos
effect
strategi
combat
merscov
infect
continu
spread
among
multipl
anim
speci
probe
adapt
human
effect
combin
would
requir
candid
antibodi
bind
dispar
epitop
distinct
mechan
henc
display
addit
synergist
effect
mab
mention
although
exact
mechan
lead
synergi
addit
uncertain
antibodi
demonstr
synergi
inhibit
infect
pseudotyp
merscov
antibodi
togeth
addit
effect
consequ
current
comprehens
studi
ntdtarget
mab
differ
epitop
work
mechan
make
excel
candid
combin
rbdtarget
neutral
antibodi
alon
battl
merscov
infect
studi
perform
complianc
anim
protocol
approv
institut
anim
care
use
committe
nation
institut
food
drug
control
china
food
drug
administr
cfda
beij
china
complianc
guid
care
use
laboratori
anim
nation
academi
press
washington
dc
usa
ed
licens
number
anim
use
certif
issu
scienc
technolog
depart
china
beij
china
syxk
approv
februari
experi
associ
live
merscov
conduct
laboratori
nation
institut
viral
diseas
control
prevent
china
cdc
institut
biosafeti
committe
approv
experi
involv
live
merscov
vero
cell
line
bought
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
incub
humidifi
atmospher
compris
merscov
strain
kindli
provid
professor
ron
fouchier
erasmu
medic
centr
rotterdam
netherland
femal
balbc
mice
age
week
use
mab
product
genet
modifi
mice
age
week
use
protect
assay
balbc
mice
purchas
beij
vital
river
laboratori
anim
technolog
co
ltd
licens
charl
river
hous
specif
pathogen
free
mous
facil
genet
modifi
mice
suppli
institut
laboratori
anim
resourc
nation
institut
food
drug
control
beij
china
mice
immun
merscov
residu
sino
biolog
combin
freund
complet
adjuv
sigma
st
loui
ca
usa
via
subcutan
immun
three
week
initi
immun
mice
boost
twice
interv
cell
collect
spleen
sacrif
anim
fuse
cultur
cell
ratio
presenc
sigma
hat
select
medium
use
fuse
hybridoma
cultur
incub
posit
hybridoma
select
via
scoat
elisa
posit
clone
subject
limit
dilut
downstream
valid
largescal
mab
product
ascit
fluid
mice
inocul
hybridoma
collect
purifi
capryl
acidammonium
sulfat
precipit
method
code
sequenc
merscov
spike
glycoprotein
ectodomain
emc
strain
spike
residu
ligat
pfastbacdu
vector
invitrogen
ctermin
fibritin
trimer
domain
hexahisstrep
tap
tag
facilit
purif
process
briefli
protein
prepar
use
bactobac
baculoviru
express
system
purifi
sequenti
appli
streptactin
superos
column
ge
healthcar
hb
buffer
mm
hepe
ph
mm
nacl
fraction
contain
merscov
glycoprotein
pool
concentr
subsequ
biochem
analys
sequenc
encod
merscov
ntd
residu
ctermin
hexahi
tag
insert
eukaryot
express
vector
pvax
freestyl
cell
transfect
plasmid
use
polyethylenimin
pei
sigma
h
supernat
collect
ntd
purifi
use
nta
sepharos
ge
heathcar
superdex
high
perform
column
ge
healthcar
hb
buffer
mm
hepe
ph
mm
nacl
sequenc
encod
vl
vh
separ
clone
backbon
antibodi
express
vector
contain
constant
region
human
chimer
antibodi
express
freestyl
cell
transient
transfect
purifi
affin
chromatographi
use
protein
sepharos
gelfiltr
chromatographi
purifi
exchang
phosphatebuff
salin
pb
digest
papain
proteas
sigma
night
digest
antibodi
pass
back
protein
sepharos
remov
fc
fragment
unbound
fab
flow
addit
purifi
use
superdex
high
perform
column
ge
healthcar
gene
encod
vl
follow
vh
connect
tripl
ggg
linker
ctermin
hexahi
tag
synthes
clone
eukaryot
express
vector
freestyl
cell
transfect
plasmid
presenc
pei
sigma
cellcultur
supernat
collect
h
transfect
scfv
collect
captur
nta
sepharos
ge
healthcar
bound
scfv
elut
hb
buffer
contain
mm
imidazol
purifi
gelfiltr
chromatographi
use
superdex
high
perform
column
ge
healthcar
merscov
ntd
scfv
fragment
mix
molar
ratio
incub
h
purifi
gelfiltr
chromatographi
purifi
complex
concentr
approxim
mg
hb
buffer
mm
hepe
ph
mm
nacl
use
crystal
screen
trial
perform
use
sittingdrop
vapordiffus
method
mix
protein
reservoir
solut
initi
crystal
condit
obtain
crystal
screen
kit
hampton
structur
screen
kit
molecular
dimens
optim
crystal
use
diffract
data
collect
obtain
potassium
sodium
tartrat
sodium
citrat
ph
ammonium
sulfat
vv
addit
acetonitril
vv
collect
diffract
data
crystal
flashcool
liquid
nitrogen
incub
reservoir
solut
contain
vv
glycerol
diffract
imag
collect
beamlin
shanghai
synchrotron
research
facil
ssrf
wavelength
imag
process
structur
solv
molecular
replac
use
phaser
search
model
merscov
ntd
structur
pdb
id
structur
variabl
domain
heavi
light
chain
avail
pdb
highest
sequenc
ident
subsequ
model
build
refin
perform
use
coot
phenix
favor
allow
disallow
ramachandran
plot
final
refin
model
structur
figur
gener
use
cell
cultur
mm
dish
cotransfect
mutant
supernat
contain
suffici
pseudotyp
merscov
harvest
h
posttransfect
subsequ
tissu
cultur
infecti
dose
determin
infect
cell
neutral
assay
per
well
pseudoytp
viru
incub
serial
dilut
purifi
antibodi
fab
scfv
h
cell
per
well
ad
incub
h
neutral
activ
antibodi
determin
luciferas
activ
present
calcul
use
doserespons
inhibit
function
graphpad
prism
graphpad
softwar
inc
concentr
harvest
pseudotyp
virion
normal
elisa
kit
beij
quantobio
biotechnolog
co
ltd
china
infect
target
cell
infect
cell
lyse
h
infect
viral
entri
effici
quantifi
compar
luciferas
activ
pseudotyp
virus
bear
mutant
wildtyp
merscov
spike
glycoprotein
postattach
pseudotyp
viru
neutral
assay
cell
upon
reach
densiti
per
well
plate
incub
per
well
pseudotyp
viru
h
remov
supernat
pb
ad
twice
well
wash
unbond
pseudotyp
virus
total
serial
dilut
purifi
antibodi
dmem
fb
ad
huh
cell
attach
pseudotyp
virus
well
dmem
fb
alon
control
neutral
activ
determin
base
luciferas
activ
incub
h
also
present
calcul
use
inhibit
function
graphpad
prism
graphpad
softwar
inc
synergist
addit
antagonist
interact
well
viru
neutral
evalu
median
effect
analysi
method
use
compusyn
softwar
previous
measur
neutral
valu
input
program
fraction
effect
fa
rang
two
antibodi
combin
ci
valu
calcul
relat
fa
valu
logarithm
ci
valu
indic
addit
effect
indic
synerg
indic
antagon
neutral
activ
mab
live
merscov
also
determin
vero
cell
upon
reach
densiti
per
well
plate
cell
monolay
infect
plaqueform
unit
pfu
live
viru
presenc
absenc
mab
three
day
incub
inhibitori
capac
mab
assess
determin
number
plaqu
compar
potent
merscov
antirbd
mab
merscov
suscept
anim
model
mous
establish
insert
human
dipeptidyl
peptidas
locu
use
result
global
express
transgen
genet
stabl
mous
use
experi
mice
n
challeng
intraperiton
inject
ip
dose
pseudotyp
merscov
administ
ip
mice
dose
per
mous
prior
challeng
pseudoviru
mice
n
pb
group
n
group
also
administ
pb
control
mab
mab
antina
dose
per
mous
challeng
use
ip
dose
pseudoviru
ivislumina
ii
imag
system
xenogen
baltimor
md
usa
use
detect
bioluminesc
prior
measur
luminesc
mice
anesthet
use
ip
inject
sodium
pentobarbit
mg
exposur
time
fluoresc
intens
region
interest
analyz
use
live
imag
softwar
calip
life
scienc
baltimor
md
usa
differ
wavelength
use
detect
pseudoviru
tdtomato
fluoresc
substrat
dluciferin
mg
xenogencalip
corp
alameda
ca
usa
inject
ip
imag
conduct
min
later
rel
intens
emit
light
repres
color
rang
red
intens
blue
weak
quantit
present
photon
flux
photon
bind
kinet
merscov
ntd
mutant
studi
use
octet
htx
instrument
assay
agit
set
rpm
hb
buffer
mm
hepe
ph
mm
nacl
supplement
vv
tween
perform
solid
black
tiltedbottom
plate
greiner
bioon
use
load
antihuman
igg
fc
captur
probe
captur
level
nm
biosensor
tip
equilibr
hb
buffer
supplement
vv
tween
prior
bind
assess
differ
concentr
wildtyp
mutant
merscov
ntd
follow
dissoci
data
analysi
curv
fit
perform
use
octet
softwar
version
realtim
bind
analysi
spr
conduct
biacor
instrument
chip
ge
healthcar
room
temperatur
analys
hb
buffer
consist
mm
hepe
ph
mm
nacl
vv
tween
use
protein
exchang
buffer
blank
channel
chip
use
neg
control
immobil
chip
respons
unit
solubl
merscov
spike
trimer
gradient
present
absenc
concentr
gradient
igg
fab
scfv
flow
chip
surfac
cycl
sensor
surfac
regener
mm
naoh
data
analyz
use
biacor
evalu
softwar
fit
langmuir
bind
model
bind
recombin
solubl
merscov
spike
trimer
human
express
surfac
cell
measur
use
fluorescenceactiv
cell
sort
fac
cellsurfac
stain
experi
perform
room
temperatur
solubl
merscov
spike
trimer
streptag
incub
monoclon
antibodi
mab
advanc
molar
ratio
h
cell
trypsin
incub
mab
mixtur
h
wash
unbound
pb
time
cell
stain
streptavidin
apc
bd
ebiosci
anoth
min
cell
subsequ
wash
pb
time
analyz
flow
cytometri
fac
aria
iii
machin
bd
ebiosci
total
pseudotyp
merscov
thaw
mix
antibodi
igg
fab
scfv
h
viru
alon
mixtur
incub
cell
suspens
anoth
h
equal
volum
buffer
proteinasek
final
concentr
thermofish
ad
incub
h
solubl
trimer
incub
ectodomain
fab
h
ice
trypsin
final
concentr
thermofish
ad
sampl
incub
min
subsequ
sampl
supplement
proteinasek
incub
min
sdspage
load
buffer
ad
sampl
prior
boil
sampl
run
gradient
trismopsgel
genscript
transfer
polyvinyliden
fluorid
membran
merscov
polyclon
antibodi
dilut
thermofish
cat
hrpconjug
goat
antirabbit
secondari
antibodi
dilut
huaxingbio
cat
use
western
blot
use
develop
imag
inform
research
design
avail
natur
research
report
summari
link
articl
